Friday - May 10, 2024

BRAF-mutant Non-Small Cell Lung Cancer (NSCLC) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Xynomic, Revolution Medicines

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the BRAF-mutant Non-Small Cell Lung Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of … Continue reading

Prostate Cancer Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Astellas, Pfizer, Janssen, Roche, Merck, Bayer, Advantagene

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 200+ key pharma and biotech companies are working on 200+ pipeline drugs in the Prostate Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and … Continue reading

Obesity Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Empros Pharma, ERX Pharma, Raziel, Novo Nordisk, Saniona, Eli Lilly

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Obesity therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule … Continue reading

Esophageal Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | BeiGene, Amgen, Oncolys, Pfizer, Novartis, TESARO

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Esophageal Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and … Continue reading